Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trialGerald S. Falchook, Leslie A. Fecher, Nicholas J. Vogelzang et al.|The Lancet Oncology|2012Cited by 541
A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid TumorsPhilippe L. Bédard, Cristiana Sessa, Josep Tabernero et al.|Clinical Cancer Research|2014Cited by 326